LivaNova (NASDAQ:LIVN) Releases FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.800-3.90 for the period, compared to the consensus estimate of 3.550. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LIVN. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Barclays lifted their price target on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Wednesday, September 3rd. Robert W. Baird increased their target price on shares of LivaNova from $61.00 to $63.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, The Goldman Sachs Group set a $55.00 price objective on shares of LivaNova and gave the company a “neutral” rating in a research note on Wednesday, October 1st. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

LivaNova Trading Down 3.4%

Shares of NASDAQ LIVN traded down $1.72 during midday trading on Thursday, hitting $49.09. The stock had a trading volume of 219,536 shares, compared to its average volume of 665,375. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The firm has a market cap of $2.68 billion, a P/E ratio of -12.62 and a beta of 1.00. The company’s 50-day simple moving average is $54.25 and its 200 day simple moving average is $48.13.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.21. The business had revenue of $352.50 million during the quarter, compared to analysts’ expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. Research analysts anticipate that LivaNova will post 2.85 EPS for the current year.

Institutional Trading of LivaNova

A number of large investors have recently added to or reduced their stakes in LIVN. State of Wyoming acquired a new stake in LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC boosted its position in shares of LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the period. Strs Ohio bought a new position in LivaNova during the first quarter worth about $130,000. Headlands Technologies LLC raised its stake in LivaNova by 270.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock worth $156,000 after purchasing an additional 2,524 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in LivaNova in the 2nd quarter valued at about $218,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.